Advantages of the Jak inhibitor in type 1 diabetes lost after stopping

(Medage today) – The effects of the baricitinib inhibitor of JAK (Olumant) declined after treatment among patients with type 1 diabetes of the new appearance, the 2 years of the phase II bandit trial has shown. After stopping treatment, c-peptide …